{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [],
   "source": [
    "import argparse\n",
    "import os\n",
    "import shutil\n",
    "from langchain.document_loaders.pdf import PyPDFDirectoryLoader\n",
    "from langchain.schema.document import Document\n",
    "from get_embedding_function import get_embedding_function\n",
    "from langchain.vectorstores.chroma import Chroma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [],
   "source": [
    "CHROMA_PATH = \"chroma\"\n",
    "DATA_PATH = \"data\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "metadata": {},
   "outputs": [],
   "source": [
    "from __future__ import annotations\n",
    "\n",
    "import re\n",
    "from typing import Any, List, Optional\n",
    "\n",
    "from langchain_text_splitters.base import Language, TextSplitter\n",
    "\n",
    "def _split_text_with_regex(\n",
    "    text: str, separator: str, keep_separator: bool\n",
    ") -> List[str]:\n",
    "    # Now that we have the separator, split the text\n",
    "    if separator:\n",
    "        if keep_separator:\n",
    "            # The parentheses in the pattern keep the delimiters in the result.\n",
    "            _splits = re.split(f\"({separator})\", text)\n",
    "            splits = [_splits[i] + _splits[i + 1] for i in range(1, len(_splits), 2)]\n",
    "            if len(_splits) % 2 == 0:\n",
    "                splits += _splits[-1:]\n",
    "            splits = [_splits[0]] + splits\n",
    "        else:\n",
    "            splits = re.split(separator, text)\n",
    "    else:\n",
    "        splits = list(text)\n",
    "    return [s for s in splits if s != \"\"]\n",
    "\n",
    "class RecursiveRegexTextSplitter(TextSplitter):\n",
    "    \"\"\"Splitting text by recursively look at characters.\n",
    "\n",
    "    Recursively tries to split by different characters to find one\n",
    "    that works.\n",
    "    \"\"\"\n",
    "\n",
    "    def __init__(\n",
    "        self,\n",
    "        separators: Optional[List[str]] = None,\n",
    "        keep_separator: bool = False,\n",
    "        is_separator_regex: bool = False,\n",
    "        match_str: Optional[str] = None,\n",
    "        **kwargs: Any,\n",
    "    ) -> None:\n",
    "        \"\"\"Create a new TextSplitter.\"\"\"\n",
    "        super().__init__(keep_separator=keep_separator, **kwargs)\n",
    "        self._separators = separators or [\"\\n\\n\", \"\\n\", \" \", \"\"]\n",
    "        self._is_separator_regex = is_separator_regex\n",
    "        self.match_str = match_str\n",
    "\n",
    "    def _split_text(self, text: str, separators: List[str]) -> List[str]:\n",
    "        \"\"\"Split incoming text and return chunks.\"\"\"\n",
    "        final_chunks = []\n",
    "        # Get appropriate separator to use\n",
    "        separator = \"\\n\"\n",
    "        new_separators = []\n",
    "        for i, _s in enumerate(separators):\n",
    "            _separator = _s if self._is_separator_regex else re.escape(_s)\n",
    "            if _s == \"\":\n",
    "                separator = _s\n",
    "                break\n",
    "            if re.search(_separator, text):\n",
    "                separator = _s\n",
    "                new_separators = separators[i + 1 :]\n",
    "                break\n",
    "\n",
    "        _separator = separator if self._is_separator_regex else re.escape(separator)\n",
    "        splits = _split_text_with_regex(text, _separator, self._keep_separator)\n",
    "\n",
    "        # Now go merging things, recursively splitting longer texts.\n",
    "        _good_splits = []\n",
    "        _separator = \"\" if self._keep_separator else separator\n",
    "\n",
    "        for s in splits:\n",
    "            if bool(re.match(self.match_str, s)) == False:\n",
    "                _good_splits.append(s)\n",
    "            else:\n",
    "                if _good_splits:\n",
    "                    merged_text = self._merge_splits(_good_splits, _separator)\n",
    "                    final_chunks.extend(merged_text)\n",
    "                    print(merged_text)\n",
    "                    _good_splits = [s]\n",
    "                if not new_separators:\n",
    "                    final_chunks.append(s)\n",
    "                else:\n",
    "                    other_info = self._split_text(s, new_separators)\n",
    "                    final_chunks.extend(other_info)\n",
    "        if _good_splits:\n",
    "            merged_text = self._merge_splits(_good_splits, _separator)\n",
    "            final_chunks.extend(merged_text)\n",
    "        return final_chunks\n",
    "\n",
    "    def split_text(self, text: str) -> List[str]:\n",
    "        return self._split_text(text, self._separators)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_documents():\n",
    "    document_loader = PyPDFDirectoryLoader(DATA_PATH)\n",
    "    return document_loader.load()\n",
    "\n",
    "# play around with various chunk sizes and overlapping\n",
    "def split_documents(documents: list[Document]):\n",
    "    text_splitter = RecursiveRegexTextSplitter(\n",
    "        chunk_size=1600,\n",
    "        chunk_overlap=160,\n",
    "        length_function=len,\n",
    "        is_separator_regex=False,\n",
    "        match_str=r'\\b[0-9]{1,}\\b\\.'\n",
    "    )\n",
    "    return text_splitter.split_documents(documents)\n",
    "\n",
    "\n",
    "def add_to_chroma(chunks: list[Document]):\n",
    "    # Load the existing database.\n",
    "    db = Chroma(\n",
    "        persist_directory=CHROMA_PATH, embedding_function=get_embedding_function()\n",
    "    )\n",
    "\n",
    "    # Calculate Page IDs.\n",
    "    chunks_with_ids = calculate_chunk_ids(chunks)\n",
    "\n",
    "    # Add or Update the documents.\n",
    "    existing_items = db.get(include=[])  # IDs are always included by default\n",
    "    existing_ids = set(existing_items[\"ids\"])\n",
    "    print(f\"Number of existing documents in DB: {len(existing_ids)}\")\n",
    "\n",
    "    # Only add documents that don't exist in the DB.\n",
    "    new_chunks = []\n",
    "    for chunk in chunks_with_ids:\n",
    "        if chunk.metadata[\"id\"] not in existing_ids:\n",
    "            new_chunks.append(chunk)\n",
    "\n",
    "    if len(new_chunks):\n",
    "        print(f\"ðŸ‘‰ Adding new documents: {len(new_chunks)}\")\n",
    "        new_chunk_ids = [chunk.metadata[\"id\"] for chunk in new_chunks]\n",
    "        db.add_documents(new_chunks, ids=new_chunk_ids)\n",
    "        db.persist()\n",
    "    else:\n",
    "        print(\"âœ… No new documents to add\")\n",
    "\n",
    "\n",
    "def calculate_chunk_ids(chunks):\n",
    "\n",
    "    # This will create IDs like \"data/monopoly.pdf:6:2\"\n",
    "    # Page Source : Page Number : Chunk Index\n",
    "\n",
    "    last_page_id = None\n",
    "    current_chunk_index = 0\n",
    "\n",
    "    for chunk in chunks:\n",
    "        source = chunk.metadata.get(\"source\")\n",
    "        page = chunk.metadata.get(\"page\")\n",
    "        current_page_id = f\"{source}:{page}\"\n",
    "\n",
    "        # If the page ID is the same as the last one, increment the index.\n",
    "        if current_page_id == last_page_id:\n",
    "            current_chunk_index += 1\n",
    "        else:\n",
    "            current_chunk_index = 0\n",
    "\n",
    "        # Calculate the chunk ID.\n",
    "        chunk_id = f\"{current_page_id}:{current_chunk_index}\"\n",
    "        last_page_id = current_page_id\n",
    "\n",
    "        # Add it to the page meta-data.\n",
    "        chunk.metadata[\"id\"] = chunk_id\n",
    "\n",
    "    return chunks\n",
    "\n",
    "\n",
    "def clear_database():\n",
    "    if os.path.exists(CHROMA_PATH):\n",
    "        shutil.rmtree(CHROMA_PATH)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['OECD/OCDE  416\\nAdopted:\\n22nd January 2001\\n1/13OECD GUIDELINE FOR TESTING OF CHEMICALS\\nTwo-Generation Reproduction Toxicity Study\\nINTRODUCTION']\n",
      "['1. In Copenhagen in June 1995, an OECD Working Group on Reproduction and Developmental\\nToxicity discussed the need to update existing OECD  Test Guidelines for reproduction and developmental\\ntoxicity and the development of new Guidelines for endpoints not yet covered.  The Working Group\\nrecommended that the Guideline for the Two-generation Reproduction Toxicity Study should be revised,based on proposals received from US and Germany.  The Working Group reached agreement on all major\\nelements of the revised version of this Guideline (1).\\nINITIAL CONSIDERATIONS']\n",
      "['2. This Guideline for two-generation reproduction testing is designed to provide general\\ninformation concerning the effects of a test substance on the integrity and performance of the male and\\nfemale reproductive systems, including gonadal function, the oestrus cycle, mating behaviour, conception,\\ngestation, parturition, lactation, and weaning, and the growth and development of the offspring.  The study\\nmay also provide information about the effects of the test substance on neonatal morbidity, mortality, andpreliminary data on prenatal and postnatal developmental toxicity and serve as a guide for subsequent tests.\\nIn addition to studying growth and development of the F1 generation, this Guideline is also intended to\\nassess the integrity and performance of the male and female reproductive systems as well as growth anddevelopment of the F2 generation.  For further information on developmental toxicity and functionaldeficiencies, either additional study segments can be incorporated into this protocol, utilising the\\nGuidelines for developmental toxicity and/or developmental neurotoxicity, or these endpoints could be\\nstudied in separate studies, using the appropriate Guidelines.\\nPRINCIPLE OF THE TEST']\n",
      "['416 OECD/OCDE\\n2/134. Clinical observations and pathological examinations are performed on all animals for signs of\\ntoxicity with special emphasis on effects on the integrity and performance of the male and female\\nreproductive systems and on the growth and development of the offspring.\\nDESCRIPTION OF THE METHOD / PREPARATIONS FOR THE TEST\\nSelection of animal species']\n",
      "['5. The rat is the preferred species for testing.  If other species are used, justification should be given\\nand appropriate modifications will be necessary.  Strains with low fecundity or well-known high incidence\\nof developmental defects should not be used.  At the commencement of the study, the weight variation of\\nanimals used should be minimal and not exceed 20% of the mean weight of each sex.\\nHousing and feeding conditions']\n",
      "['6. The temperature in the experimental animal room should be (22 Â± 3)Â°C.  Although the relative\\nhumidity should be at least 30 % and preferably not exceed 70% other than during room cleaning, the aim\\nshould be 50-60 %.  Lighting should be artificial, the sequence being 12 hours light, 12 hours dark.  For\\nfeeding, conventional laboratory diets may be used with an unlimited supply of drinking water.  The choice\\nof diet may be influenced by the need to ensure a suitable admixture of a test substance when administeredby this method.']\n",
      "['7. Animals may be housed individually or be caged in small groups of the same sex.  Mating\\nprocedures should be carried out in cages suitable for the purpose.  After evidence of copulation, matedfemales shall be single-caged in delivery or maternity cages.  Mated rats may also be kept in small groups\\nand separated one or two days prior to parturition.  Mated  animals shall be provided with appropriate and\\ndefined nesting materials when parturition is near.\\nPreparation of animals']\n",
      "['8. Healthy young animals, which have been acclimated to laboratory conditions for at least 5 days\\nand have not been subjected to previous experimental procedures, should be used.  The test animals should\\nbe characterised as to species, strain, source , sex, weight and/or age.  Any sibling relationships among the\\nanimals should be known so that mating of siblings is avoided.  The animals should be randomly assigned\\nto the control and treated groups (stratification by body weight is recommended).   Cages should be\\narranged in such a way that possible effects due to cage placement are minimised.  Each animal should be\\nassigned a unique identification number.  For the P generation, this should be done before dosing starts.\\nFor the F1 generation, this should be done at weaning for animals selected for mating.  Records indicating\\nthe litter of origin should be maintained for all select ed F1 animals.  In addition, individual identification of\\npups as soon after birth as possible is  recommended when individual weighing of pups  or functional tests\\nare considered.']\n",
      "['OECD/OCDE  416\\n3/13PROCEDURE\\nNumber and sex of animals']\n",
      "['10. Each test and control group should contain a sufficient number of animals to yield preferably not\\nless than 20 pregnant females at or near parturition.  For substances that cause  undesirable treatment\\nrelated effects (e.g. sterility, excessive toxicity at the high dose), this may not be possible.   The objective is\\nto produce enough pregnancies to assure a meaningful evaluation of the potential of the substance to affect\\nfertility, pregnancy and maternal behaviour and suckling, growth and development of the F1 offspring\\nfrom conception to maturity, and the development of their offspring (F2) to weaning.  Therefore, failure to\\nachieve the desired number of pregnant animals (i.e. 20) does not necessarily invalidate the study and\\nshould be evaluated on a case-by-case basis.\\nPreparation of Doses']\n",
      "['11. It is recommended that the test substance be administered orally (by diet, drinking water or\\ngavage) unless another route of administration (e.g. dermal or inhalation) is considered more appropriate.']\n",
      "['12. Where necessary, the test substance is dissolved or suspended in a suitable vehicle.  It is\\nrecommended that, wherever possible, the use of an aqueous solution/suspension be considered first,\\nfollowed by consideration of a solution/emulsion in oil (e.g. corn oil) and then by possible solution in other\\nvehicles. For vehicles other than water, the toxic characteristics of the vehicle must be known.  The\\nstability of the test substance in the vehicle should be determined.\\nDosage']\n",
      "['13. At least three dose levels and a concurrent control shall be used.  Unless limited by the\\nphysical-chemical nature or biological effects of the test substance, the highest dose level should be chosen\\nwith the aim to induce toxicity but not death or severe suffering.  In case of unexpected mortality, studieswith a mortality rate of less than approximately 10 percent in the parental (P) animals would normally still\\nbe acceptable.  A descending sequence of dose levels should be selected with a view to demonstrating any\\ndosage related effect and no-observed-adverse-effects level (NOAEL) or doses near the limit of detection\\nthat would allow the determination of a benchmark dose.  Two to four fold intervals are frequently optimal\\nfor setting the descending dose levels and addition of a fourth test group is often preferable to using very\\nlarge intervals (e.g. more than a factor of 10) between dosages.  For the dietary studies the dose interval\\nshould be not more than 3 fold.  Dose levels should be selected taking into account any existing toxicity\\ndata, especially results from repeated dose studies.  Any available information on metabolism and kinetics\\nof the test compound or related materials should also be considered.  In addition, this information will also\\nassist in demonstrating the adequacy of the dosing regimen.']\n",
      "['14. The control group shall be an untreated group or a vehicle-control group if a vehicle is used in\\nadministering the test substance.  Except for treatment with the test substance, animals in the control group\\nshould be handled in an identical manner to the test group subjects.  If a vehicle is used, the control group\\nshall receive the vehicle in the highest volume used.  If a test substance is administered in the diet, andcauses reduced dietary intake or utilisation, then the use of a paired control group may be considered\\nnecessary.  Alternatively data from controlled studies designed to evaluate the effects of decreased food\\nconsumption on reproductive parameters may be used in lieu of a concurrent pair-fed control group.']\n",
      "['416 OECD/OCDE\\n4/13Limit test']\n",
      "['16. If an oral study at one dose level of at least 1000 mg/kg body weight/day or, for dietary or\\ndrinking water administration, an equivalent percentage in the diet or drinking water using the procedures\\ndescribed for this study, produces no observable toxic effects and if toxicity would not be expected based\\nupon data from structurally and /or metabolically related compounds, then a full study using several dose\\nlevels may not be considered necessary.  The limit test applies except when human exposure indicates the\\nneed for a higher oral dose level to be used.  For other types of administration, such as inhalation or dermal\\napplication, the physical chemical properties of the test substance, such as solubility, often may dictate themaximum attainable concentration.\\nAdministration of doses']\n",
      "['17. The animals should be dosed with the test substance on a 7-days-a-week basis.  The oral route of\\nadministration (diet, drinking water, or gavage) is preferred.  If another route of administration is used,\\njustification shall be provided, and appropriate modifications may be necessary.  All animals shall be dosed\\nby the same method during the appropriate experimental period.  When the test substance is administered\\nby gavage, this should be done using a stomach tube.  The volume of liquid administered at one time\\nshould not exceed 1 ml/l00 g body weight (0.4 ml/100 g body weight is the maximum for corn oil), exceptin the case of aqueous solutions where 2 ml/100 g body weight may be used.  Except for irritant or\\ncorrosive substances which will normally reveal exacerbated effects with higher concentrations, variability\\nin test volume should be minimised by adjusting the concentration to ensure a constant volume at all dose\\nlevels.  In gavage studies, the pups will normally only receive test substance indirectly through the milk,\\nuntil direct dosing commences for them at weaning.  In diet or drinking water studies, the pups will\\nadditionally receive test substance directly when they commence eating for themselves during the last\\nweek of the lactation period.']\n",
      "['18. For substances administered via the diet or drinking water, it is important to ensure that the\\nquantities of the test substance involved do not interfere with normal nutrition or water balance.  When the\\ntest substance is administered in the diet either a constant dietary concentration (ppm) or a constant dose\\nlevel in terms of the body weight of the animal may be used; the alternative used must be specified.  For a\\nsubstance administered by gavage, the dose should be given at similar times each day, and adjusted at least\\nweekly to maintain a constant dose level in terms of animal body weight. Information regarding placentaldistribution should be considered when adjusting the gavage dose based on weight.\\nExperimental schedules']\n",
      "['19.Daily dosing of the parental (P) males and females shall begin when they are 5  to 9 weeks old.\\nDaily dosing of the F1 males and females shall begin at weaning; it should be kept in mind that in cases of\\ntest substance administration via diet or drinking water, direct exposure of the F1 pups to the test substance\\nmay already occur during the lactation period.  For both sexes (P and F1), dosing shall be continued for atleast 10 weeks before the mating period.  Dosing is continued in both sexes during the 2 week mating\\nperiod.  Males should be humanely killed and examined when they are no longer needed for assessment of\\nreproductive effects.  For parental (P) females, dosing should continue throughout pregnancy and up to the\\nweaning of the F1\\n offspring.  Consideration should be given to modifications in the dosing schedule based\\non available information on the test substance, including existing toxicity data, induction of metabolism orbioaccumulation.  The dose to each animal should normally be based on the most recent individual body\\nweight determination.  However, caution should be exercised when adjusting the dose during the last\\ntrimester of pregnancy.']\n",
      "['OECD/OCDE  416\\n5/13reproductive effects.  F1 offspring not selected for mating and all F2 offspring should be humanely killed\\nafter weaning.\\nMating procedure\\nParental (P) mating']\n",
      "['21. For each mating, each female shall be placed with a single male from the same dose level (1:1\\nmating) until copulation occurs or 2 weeks have elapsed.  Each day, the females shall be examined for\\npresence of sperm or vaginal plugs.  Day 0 of pregnancy is defined as the day a vaginal plug or sperm arefound.  In case pairing is unsuccessful, re-mating of females with proven males of the same group could be\\nconsidered. Mating pairs should be clearly identified in the data. Mating of siblings should be avoided.\\nF1 mating']\n",
      "['22. For mating the F1 offspring, at least one male  and one female should be selected at weaning from\\neach litter for mating with other pups of the same dose level but different litter, to produce the F2\\ngeneration.  Selection of pups from each litter should be random when no significant differences are\\nobserved in body weight or appearance between the litter mates.  In case these differences are observed,\\nthe best representatives of each litter should be selected.  Pragmatically, this is best done on a body weightbasis but it may be more appropriate on the basis of appearance.  The F1 offspring should not be mated\\nuntil they have attained full sexual maturity.']\n",
      "['23. Pairs without progeny should be evaluated to determine the apparent cause of the infertility.  This\\nmay involve such procedures as additional opportunities to mate with other proven sires or dams,\\nmicroscopic examination of the reproductive organs, and examination of the oestrous cycles or\\nspermatogenesis.\\nSecond mating']\n",
      "['24. In certain instances, such as treatment-related alterations in litter size or the observation of an\\nequivocal effect in the first mating, it is recommended that the P or F1 adults be remated to produce a\\nsecond litter.  It is recommended to remate females or males which have not produced a litter with proven\\nbreeders of the opposite sex.  If production of a second litter is deemed necessary in either generation,\\nanimals should be remated approximately one week after weaning of the last litter.\\nLitter size']\n",
      "['416 OECD/OCDE\\n6/13OBSERVATIONS\\nClinical observations']\n",
      "['26. A general clinical observation should be made each day and, and in the case of gavage dosing its\\ntiming should take into account the anticipated  peak period of effects after dosing.  Behavioural changes,\\nsigns of difficult or prolonged parturition and all signs of toxicity should be recorded.  An additional, more\\ndetailed examination of each animal should be conducted on at least a weekly basis and could conveniently\\nbe performed on an occasion when the animal is weighed.  Twice daily, during the weekend once daily\\nwhen appropriate, all animals should be observed for morbidity and mortality.\\nBody weight and food/water consumption of parent animals']\n",
      "['27. Parental animals (P and Fl) shall be weighed on the first day of dosing and at least weekly\\nthereafter.  Parental females (P and F1) shall be weighed at a minimum on gestation days 0, 7, 14, and 20\\nor 21, and during lactation on the same days as the weighing of litters and on the day the animals are killed.These observations should be reported individually for each adult animal.  During the premating and\\ngestation periods food consumption shall be measured weekly at a minimum.  Water consumption shall be\\nmeasured weekly at a minimum if the test substance is administered in the water.\\nOestrus cycle']\n",
      "['28. Oestrous cycle length and normality are evaluated in P and F1 females by vaginal smears prior to\\nmating, and optionally during mating, until evidence of mating is found.  When obtaining vaginal/cervical\\ncells, care should be taken to avoid disturbance of mucosa and subsequently, the induction of\\npseudopregnancy (2).\\nSperm parameters']\n",
      "['29. For all P and F1  males at termination, testis and epididymis weight shall be recorded and one of\\neach organ reserved for histopathological examination (see paragraphs 39, 42, 44).  Of a subset of at least\\nten males of each group of P and F1 males, the remaining testes and epididymides should be used for\\nenumeration of homogenisation-resistant spermatids and cauda epididymides sperm reserves, respectively.For this same subset of males, sperm from the cauda epididymides or vas deferens should be collected for\\nevaluation of sperm motility and sperm morphology. If treatment-related effects are observed or when\\nthere is evidence from other studies of possible effects on spermatogenesis, sperm evaluation should be\\nconducted in all males in each dose group; otherwise enumeration may be restricted to control and high-\\ndose P and F1 males.']\n",
      "['OECD/OCDE  416\\n7/1331. Epididymal (or ductus deferens) sperm motility should be evaluated or video taped immediately\\nafter sacrifice.  Sperm should be recovered while minimising damage, and diluted for motility analysis\\nusing acceptable methods (5) .  The percentage of progressively motile sperm should be determined either\\nsubjectively or objectively.  When computer-assisted motion analysis is performed (6)(7)(8)(9)(10)(11) the\\nderivation of progressive motility relies on user-defined thresholds for average path velocity and\\nstraightness or linear index.  If samples are videotaped (12) or the images are otherwise recorded at the\\ntime of necropsy, subsequent analysis of only control and high-dose P and F1 males may be performed\\nunless treatment-related effects are observed; in that case, the lower dose groups should also be evaluated.In the absence of a video or digital image, all samples in all treatment groups should be analysed at\\nnecropsy.']\n",
      "['32. A morphological evaluation of an epididymal (or vas deferens) sperm sample should be\\nperformed.  Sperm (at least 200 per sample) should be examined as fixed, wet preparations (13) and\\nclassified as either normal or abnormal.  Examples of morphologic sperm abnormalities would include\\nfusion, isolated heads, and misshapen heads and/or tails.  Evaluation should be performed on the selected\\nsubset of males of all dose groups either immediately after killing the animals, or, based on the video ordigital recordings, at a later time. Smears, once fixed, can also be read at a later time. In these instances,\\nthe controls and high dose group may be analysed first.  If no treatment-related effects (e.g., effects on\\nsperm morphology) are seen the other dose groups need not be analysed.  When treatment-related effects\\nare noted in the high-dose group, then the lower dose groups should also be evaluated.']\n",
      "['33. If any of the above sperm evaluation parameters have already been examined as part of a\\nsystemic toxicity study of at least 90 days, they need not necessarily be repeated in the two-generation\\nstudy.  It is recommended, however, that samples or digital recordings of sperm of the P generation aresaved, to enable later evaluation, if necessary.\\nOffspring']\n",
      "['34. Each litter should be examined as soon as possible after delivery (lactation day 0) to establish the\\nnumber and sex of pups, stillbirths, live births, and the presence of gross anomalies.  Pups found dead on\\nday 0, if not macerated, should preferably be examined for possible defects and cause of death and\\npreserved.  Live pups should be counted and weighed individually at birth (lactation day 0) or on day 1,\\nand on regular weigh days thereafter, e.g., on days 4, 7, 14, and 21 of lactation. Physical or behavioural\\nabnormalities observed in the dams or offspring should be recorded.']\n",
      "['35. Physical development of the offspring should be recorded mainly by body weight gain.  Other\\nphysical parameters (e.g. ear and eye opening, tooth eruption, hair growth) may give supplementary\\ninformation, but these data should preferably be evaluated in the context of data on sexual maturation (e.g.\\nage and body weight at vaginal opening or balano-preputial separation) (14).  Functional investigations\\n(e.g. motor activity, sensory function, reflex ontogeny) of the F1 offspring before and/or after weaning,\\nparticularly those related to sexual maturation, are recommended if such investigations are not included inseparate studies.  The age of vaginal opening and preputial separation should be determined for F1\\nweanlings selected for mating. Anogenital distance should be measured at postnatal day 0 in F2 pups if\\ntriggered by alterations in F1 sex ratio or timing of sexual maturation.']\n",
      "['416 OECD/OCDE\\n8/13Gross necropsy']\n",
      "['37. At the time of termination or death during the study, all parental animals (P and F1), all pups with\\nexternal abnormalities or clinical signs, as well as at least one randomly selected pup/sex/litter from both\\nthe F1 and F2 generation, shall be examined macroscopically for any structural abnormalities or\\npathological changes.  Special attention should be paid to the organs of the reproductive system.  Pups that\\nare humanely killed in a moribund condition and dead pups, when not macerated, should be examined for\\npossible defects and/or cause of death and preserved.']\n",
      "['38. The uteri of all primiparous  females should be examined, in a manner which does not\\ncompromise histopathological evaluation, for the presence and number of implantation sites.\\nOrgan weights']\n",
      "['39. At the time of termination, body weight and the weight of the following organs of all P and F1\\nparental animals shall be determined (paired organs should be weighed individually):\\nâ€¢ Uterus, ovaries;\\nâ€¢ Testes, epididymides (total and cauda);\\nâ€¢ Prostate;\\nâ€¢ Seminal vesicles with coagulating glands and their fluids (as one unit);\\nâ€¢ Brain, liver, kidneys, spleen, pituitary, thyroid and adrenal glands and known target organs.']\n",
      "['40. Terminal body weights should be determined for F1 and F2 pups that are selected for necropsy,\\nand the following organs from the one randomly selected pup/sex/litter (see paragraph 37) shall beweighed:  - Brain, spleen and thymus.']\n",
      "['41. Gross necropsy and organ weight results should be assessed in context with observations made in\\nother repeated dose studies, when feasible.\\nHistopathology\\nParental Animals']\n",
      "['42. The following organs and tissues of parental (P and F1) animals , or representative  samples\\nthereof, shall be fixed and stored in a  suitable medium for histopathological examination.\\nâ€¢ Vagina, uterus with cervix, and ovaries (preserved in an appropriate fixative);\\nâ€¢ One testis (preserved in Bouin â€™s or comparable fixative), one epididymis, seminal vesicles, prostate,\\nand coagulating gland;\\nâ€¢ Previously identified target organ(s) from all P and F1 animals selected for mating.']\n",
      "['OECD/OCDE  416\\n9/1344. Detailed testicular histopathological examination (e.g. using Bouin â€™s fixative, paraffin embedding\\nand transverse sections of 4-5 Âµ m thickness) should be conducted in order to identify treatment-related\\neffects such as retained spermatids, missing germ cell layers or types, multinucleated giant cells or\\nsloughing of spermatogenic cells into the lumen (15).  Examination of the intact epididymis should include\\nthe caput, corpus, and cauda, which can be accomplished by evaluation of a longitudinal section.  Theepididymis should be evaluated for leukocyte infiltration, change in prevalence of cell types, aberrant cell\\ntypes, and phagocytosis of sperm.  PAS and haematoxylin staining may be used for examination of the\\nmale reproductive organs.']\n",
      "['45. The postlactational ovary should contain primordial and growing follicles as well as the large\\ncorpora lutea of lactation. Histopathological examination should detect qualitative depletion of the\\nprimordial follicle population.  A quantitative evaluation of primordial follicles should be conducted for F1females; the number of animals, ovarian section selection, and section sample size should be statistically\\nappropriate for the evaluation procedure used.  Examination should include enumeration of the number of\\nprimordial follicles, which can be combined with small growing follicles, for comparison of treated and\\ncontrol ovaries (16)(17)(18)(19)(20).\\nWeanlings']\n",
      "['46. Grossly abnormal tissue  and target organs from all pups with external abnormalities or clinical\\nsigns, as well as from at least one randomly selected pup/sex/litter from both the F1 and F2 generation\\nwhich have not been selected for mating (see paragraph 37), shall be fixed and stored in a suitable medium\\nfor histopathological examination.  Full histopathological characterisation of preserved tissue should beperformed with special emphasis on the organs of the reproductive system.\\nDATA and REPORTING\\nData']\n",
      "['47. Data shall be reported individually and summarised in tabular form, showing for each test group\\nand each generation the number of animals at the start of the test, the number of animals found dead during\\nthe test or killed for humane reasons, the time of any death or humane kill, the number of fertile animals,\\nthe number of pregnant females, the number of animals showing signs of toxicity, a description of the signs\\nof toxicity observed, including time of onset, duration, and severity of any toxic effects, the types of\\nhistopathological changes, and all relevant litter data.']\n",
      "['48. Numerical results should be evaluated by an appropriate, generally accepted statistical method;\\nthe statistical methods should be selected as part of the design of the study.  Dose-response statistical\\nmodels may be useful for analysing data.  The report should include sufficient information on the method\\nof analysis and the computer program employed, so that an independent reviewer/statistician can re-\\nevaluate and reconstruct the analysis.\\nEvaluation of results']\n",
      "['416 OECD/OCDE\\n10/1350. A properly conducted reproductive toxicity test should provide a satisfactory estimation of a\\nno-effect level and an understanding of adverse effects on reproduction, parturition, lactation, postnatal\\ndevelopment including growth and sexual development.\\nTest Report']\n",
      "['OECD/OCDE  416\\n11/13- number of P and F1 females cycling normally and cycle length;\\n- total cauda epididymal sperm number, percent progressively motile sperm, percent\\nmorphologically normal sperm, and percent of sperm with each identified abnormality;\\n- time-to-mating, including the number of days until mating\\n- gestation length;- number of implantations, corpora lutea, litter size\\n- number of live births and post-implantation loss;\\n- number of pups with grossly visible abnormalities,  if determined the number of runts should\\nbe reported;\\n- data on physical landmarks in pups and other postnatal developmental data;  physical\\nlandmarks evaluated should be justified;\\n- data on functional observations in pups and adults, as applicable;- statistical treatment of results, where appropriate.\\nDiscussion of results.Conclusions, including NOAEL values for maternal and offspring effects.\\nInterpretation of results']\n",
      "['OECD/O CDE                            443  \\nAdopted:  \\n25 June 2018  \\nÂ© OECD, (2018 ) \\n \\nYou are free to use this material subject to the terms and conditions available at http://www.oecd.org/termsandconditions/ .  \\n \\nIn accor dance with the decision of the C ouncil on a delegation of authority to amend Annex I of the decision of the council on the M utual \\nAcceptance of  Data in the assessment of chemicals [C( 2018)49], this G uideline was amended by the OECD â€™s Joint M eeting of the Chemicals \\nCommittee and the Working Party on C hemicals, Pesticides and Biotechnol ogy by written procedure on 25 J une 2018.  OECD GUIDELINE  FOR THE TESTING OF CHEMICALS  \\nEXTENDED ONE -GENERATION REPRODUCTIVE TOXICITY \\nSTUDY  \\nINTRODUCTION']\n",
      "['1.  This Test Guideline (TG) is based on the International Life Science Institute (ILSI) -Health and \\nEnvironmental Sciences Institute (HESI), Agricultural Chemical Safety Assessment (ACSA) Technical \\nCommittee proposal for a life stage F1 extended one generation reproductive study as published in \\nCooper et al., 2006 (1). Several improvements and clarifications have been made to the study design  to \\nprovide flexibility and to stress the importance of starting with existing knowledge, while using  in-life \\nobservations to guide and tailor the testing. This guideline provides a detailed description of the \\noperational conduct of an Extended One -Generation Reproductive Toxicity Study. The TG describes \\nthree cohorts of F 1 animals:  \\n\\uf0b7 Cohort 1: assesses re productive/developmental endpoints; this cohort may be extended to include \\nan F 2 generation.  \\n\\uf0b7 Cohort 2: assesses the potential impact of chemical exposure on the developing nervous system.  \\n\\uf0b7 Cohort 3: assesses the potential impact of chemical exposure on the  developing immune system.   \\n \\n2  Decisions on whether to assess the second generation and to omit the  developmental \\nneurotoxicity cohort and/or developmental immunotoxicity  cohort should reflect existing knowledge for \\nthe chemical being evaluated, as well as the needs of various regulatory authorities. The purpose of the \\nTest Guideline is to provide details on how the study can be conducted and to address how each cohort \\nshould be evaluated.']\n",
      "['3. Procedure for the decision on the internal triggering for producing a 2nd generation is described \\nin Guidance Document 117 (39) for those regulatory authorities using internal triggers.  \\nINITIAL CONSIDERATIO NS AND OBJECTIVES']\n",
      "['2 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      organs for males and females. This might include spermatogenesis (t esticular histopathology) for males \\nand oestrous cycles, follicle counts/oocyte maturation and ovarian integrity (histopathology) for females. \\nThe Extended One -Generation Reproductive Toxicity Study then serves as a test for reproductive \\nendpoints that req uire the interaction of males with females, females with conceptus, and females with \\noffspring and the F 1 generation until after sexual maturity (see Guidance Document 151 supporting this \\nTest Guideline (40)).']\n",
      "['5. The TG is designed to provide an evaluation of the pre- and postnatal effects of chemicals on \\ndevelopment as well as a thorough evaluation of systemic toxicity in pregnant and lactating females and \\nyoung and adult offspring. Detailed examination of key dev elopmental endpoints, such as offspring \\nviability, neonatal health, developmental status at birth, and physical and functional development until \\nadulthood, is expected to identify specific target organs in the offspring. In addition, the study will \\nprovide  and/or confirm information about the effects of a test chemical  on the integrity and performance \\nof the adult male and female reproductive systems. Specifically, but not exclusively, the following \\nparameters are considered: gonadal function, the oestrous cycle, epididymal sperm maturation, mating \\nbehaviour, conception, pregnancy, parturition, and lactation. Furthermore, the information obtained from \\nthe developmental neurotoxicity and developmental immunotoxicity assessments will characterize \\npotential eff ects in those systems. The data derived from these tests should allow the determination of \\nNo-Observed Adverse Effect Levels (NOAELs), Lowest Observed Adverse Effect Levels (LOAELs) \\nand/or benchmark doses for the various endpoints and/or be used to charact erize effects detected in \\nprevious repeat -dose studies  and/or serve as a guide for subsequent testing.']\n",
      "['A schematic drawing of the protocol is presented in Figure']\n",
      "['6. A schematic drawing of the protocol is presented in Figure 1. The test chemical  is administered \\ncontinuously in graduated doses to several groups of sexually -mature males and females. This parental \\n(P) generation is dosed for a defined pre -mating period (selected based on the available information for \\nthe test chemical ; but for a minimum of two weeks) and a two -week mating period . P males are further \\ntreated at least until weaning of the F 1. They should be treated for a minimum of 10 weeks. They may be \\ntreated for longer if there is a need to clarify effects on reproduction. Treatment of the P females is \\ncontinued during pregnancy and lactation until termination after the weaning of their litters ( i.e. 8-10 \\nweeks of treatment). The F 1 offspring receive further treatment with the test chemical  from weaning to \\nadulthood . If a second generation is assessed (see GD 117 (39)), the F1 offspring will be maintained on \\ntreatment until weaning of the F 2, or until termination of the study.']\n",
      "['7. Clinical observations and pathology examinations are performed on all animals for signs of \\ntoxicity, with special emphasis on the integrity and performance of the male and female reproductive \\nsystems and the health, growth, development and function of the offspring. A t weaning, selected \\noffspring are assigned to specific subgroups (cohorts 1 -3, see paragraph s 34 and 3 5 and Figure 1) for \\nfurther investigations, including sexual maturation, reproductive organ integrity and function, \\nneurological and behavioural endpoints, and immune functions.']\n",
      "['8. In conductin g the study, the guiding principles and considerations outlined in the OECD \\nGuidance Document nÂ° 19 on the recognition, assessment, and use of clinical signs as humane endpoints \\nfor experimental animals used in safety evaluations (34) should be followed.']\n",
      "['OECD/OCDE                      443 â”‚ 3 \\n \\nÂ© OECD 2018    \\n      Figure 1: Scheme of the  Extended One -Generation Reproductive Toxicity Study  \\nDosingNecropsy \\nP animals\\nPre-mating Mating Post-mating\\n2 weeks 2 weeks 6 weeks\\n2 weeks 2 weeks Pregnancy LactactionP â™‚\\n P â™€\\nF1 In-utero development Pre-weaning Post-weaning\\nTarget is \\n20 litters \\nper group1A\\n1B\\n2A\\n2B\\n3\\nSurplusParental \\ngenerationCohort Designation Animals/CohortSexual \\nmaturationApproximate age at necropsy \\n(weeks)\\nReproductive\\nReproductive\\nNeurotoxicity\\nNeurotoxicity\\nImmunotoxicity\\nSpares20 M + 20 F\\n20 M + 20 F\\n10 M + 10 F @\\n10 M + 10 F @\\n10 M + 10 F @\\n@ one per litter and representative of 20 litters in total where possibleYes\\nYes\\nYes\\nNo\\nYes\\nNo13\\n14 or 20-25 if triggered\\n11-12\\n3\\n8\\n3\\n \\nDESCRIPTION OF THE M ETHOD/PREPARATIONS F OR THE TEST  \\nAnimals  \\nSelection of animal species and strain']\n",
      "['10.  The choice of species for the reproductive toxicity test should be carefully considered in light \\nof all available information. However, because of the extent of background data and the comparability to \\ngeneral toxicity tests, the rat is normally the prefe rred species, and criteria and recommendations given in \\nthis TG refer to this species . If another species is used, justification should be given and appropriate \\nmodifications to the protocol will be necessary. Strains with low fecundity or a well -known hig h \\nincidence of spontaneous developmental defects should not be used.  \\nAge, body weight and inclusion criteria']\n",
      "['4 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      Housing and feeding conditions']\n",
      "['12. The temperature in the experimental animal room should be 22  Â°C (Â± 3Â°). Relative humidity \\nshould be between 30 -70%, with an ideal range of 50 -60%.  Artificial lighting should be set at 12 hours \\nlight, 12 hours dark. Conventional laboratory diets may be used with an unlimited supply of drinking \\nwater. C areful attention should be given to diet phytoestrogen content, as a high level of phytoestrogen in \\nthe diet might affect some reproductive endpoints . Standardized, open -formula diets in which estrogenic \\nsubstances have been reduced are recommended (2) (30). The choice of diet may be influenced by the \\nneed to ensure a suitable admixture of a test chemica l when administered by this method. Content, \\nhomogeneity and stability of the test chemical  in the diets should be verified. The feed and drinking \\nwater should be regularly analysed for contaminants. Samples of each batch of the diet used during the \\nstudy should be retained under appropriate conditions ( e.g. frozen at -20Â°C), until finalisation of the \\nreport, in case the results necessitate a further analysis of diet ingredients.']\n",
      "['13. Animals should be caged in small groups of the same sex and treatment group. They may be \\nhoused individually to avoid possible injuries ( e.g. males after the mating period). Mating procedures \\nshould be carried out in suitable cages. After evidence of copulation, females that are presumed to be \\npregnant are housed separately in parturition or maternity cages where they are provided with appropriate \\nand defined nesting materials. Litters are housed with their mothers until weaning. F 1 animals should be \\nhoused in small groups of the same sex and treatment group from weaning to termination. If \\nscientifically justified, animals can be housed individually. The level of phytoestrogens contained in the \\nselected bedding material should be minim al. \\nNumber and identification of animals']\n",
      "['14. Normally, each test and control group should contain a sufficient number of mating pairs to \\nyield at least 20 pregnant females per dose group. The objective is to produce enough pregnancies to \\nensure a meaningful evaluation of t he potential of the substance to affect fertility, pregnancy and \\nmaternal behaviour of the P generation and growth and development of the F 1 offspring, from conception \\nto maturity. Failure to achieve the desired number of pregnant animals does not necessar ily invalidate the \\nstudy and should be evaluated on a case -by-case basis, considering a possible causal relationship to the \\ntest chemical .']\n",
      "['15. Each P animal is assigned a unique identification number before dosing sta rts. If laboratory \\nhistorical data suggest that a significant proportion of females may not show regular (4 or 5 -day) oestrous \\ncycles, then an assessment of oestrous cycles before start of treatment is advised. Alternatively, the group \\nsize may be increase d to ensure that at least 20 females in each group would have regular (4 or 5 -day) \\noestrous cycles at start of treatment. All F1 offspring are uniquely identified when neonates are first \\nexamined on postnatal day (PND)  0 or 1. Records indicating the litter  of origin should be maintained for \\nall F1 animals, and F 2 animals where applicable,  throughout the study.  \\nTest chemical  \\nAvailable information on the test chemical']\n",
      "['OECD/OCDE                      443 â”‚ 5 \\n \\nÂ© OECD 2018    \\n      distribution, metabolism and elimination (ADME) and bioaccumulation may be derived from chemical \\nstructure, physico -chemical data, extent of plasma protein binding or toxicokinetic (TK) studies, while \\nresults from toxicity studies give additional information, e.g. on NOAEL, metabolism or induction of \\nmetabolism.  \\nConsideration of toxicokinetic data']\n",
      "['17. Although not required, TK data from previously conducted dose range -finding or other studies \\nare extremely useful in the planning of the study design, selection of dose levels and interpretation of \\nresults.  Of particular utility are data which: 1) verify exposure of developing fetuses and pups to the test \\ncompound (or relevant metabolites), 2) provide an estimate of internal dosimetry, and 3) evaluate for \\npotential dose -dependent saturation of kinetic processes.  Additional TK data, such as metabolite \\nprofiles, concentration -time courses, etc. should also be considered, if they are available. Supplemental \\nTK data may also be collected during the main study, provided that it does not interfere with the \\ncollection and interpretation of the main study endpoint s.  \\nAs a general guide, the following TK data set would be useful in planning the Extended One -Generation \\nReproductive Toxicity Study:   \\n \\n\\uf0b7 Late pregnancy ( e.g. Gestation Day 20) - maternal blood and foetal blood  \\n\\uf0b7 Mid-lactation (PND 10) - maternal blood, pup  blood and/or milk  \\n\\uf0b7 Early post -weaning ( e.g. PND 28) - weanling blood samples  \\nFlexibility should be employed in determining the specific analytes ( e.g. parent compound and/or \\nmetabolites) and sampling scheme.  For example, the number and timing of sample collection on a given \\nsampling day will be dependent upon route of exposure and prior knowledge of TK properties in non -\\npregnant animals. For dietary studies, sampling at a single consistent time on each of these days is', 'pregnant animals. For dietary studies, sampling at a single consistent time on each of these days is \\nsufficient, whereas gavage dosing m ay warrant additional sampling times to obtain a better estimate of \\nthe range of internal doses.  However, it is not necessary to generate a full concentration time -course on \\nany of the sampling days.  If necessary, blood can be pooled by sex within litter s for fetal and neonatal \\nanalyses.  \\nRoute of administration']\n",
      "['18. Selection of the route should take into consideration the route(s) most relevant for human \\nexposure . Although t he protocol is designed for administration  of the test chemical  through the diet, it \\ncan be modified for administration by other routes (drinking water, gavage, inhalation, dermal), \\ndepending on the characteristics of the compound and the information required.  \\nChoice of the vehicle']\n",
      "['6 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      Dose selection']\n",
      "['20. Normally, the study should include at least three dose levels and a concurrent control. W hen \\nselecting appropriate dose levels, the investigator should consider all available information, including the \\ndosing information from previous studies, TK data from pregnant or non -pregnant animals, the extent of \\nlactational transfer, and estimates of h uman exposure. If TK data are available which indicate dose -\\ndependent saturation of TK processes, care should be taken to avoid high dose levels which clearly \\nexhibit saturation, provided of course, that human exposures are expected to be well below the po int of \\nsaturation. In such cases, the highest dose level should be at, or just slightly above the inflection point for \\ntransition to nonlinear TK behaviour.']\n",
      "['21. In the absence of relevant TK data, the dose levels s hould be based on toxic effects, unless \\nlimited by the physical/chemical nature of the test chemical . If dose levels are based on toxicity , the \\nhighest dose should be chosen with the aim to induce some systemic toxicity, but not death or severe \\nsuffering o f the animals .']\n",
      "['22. In the dose selection the investigator should also consider and ensure that data generated is \\nadequate to fulfil the regulatory requirements across OECD countries as appropriate (e.g., hazard and \\nrisk assessment, classification and labelling, ED assessment, etc.)']\n",
      "['23. A descending sequence of dose levels should be selected in order to demonstrate any dose -\\nrelated effect and to establish NOAELs or doses near the limit of detection that would allow for \\nderivation of a benchmark dose for the most sensitive endpoint(s). To avoid large dose spacing between \\nNOAELs and LOAELs, two - or four -fold intervals are frequently optimal. The addition of a fourth test \\ngroup is oft en preferable to using a very large interval ( e.g. more than a factor of 10) between doses.']\n",
      "['24. Except for treatment with the test chemical , animals in the control group are handled in an \\nidentical manner to the test group subjects. This group should be untreated or sham -treated or a vehicle -\\ncontrol group if a vehicle is used in administering the test chemical . If a vehicle is used, the contr ol group \\nshould receive the vehicle in the highest volume used.  \\nLimit test']\n",
      "['25. If there is no evidence of toxicity at a dose of at least 1000 mg/kg body weight/day in repeat -\\ndose studies, or if toxicity would not be expected based upon data from structurally - and/or \\nmetabolically -related compounds, indicating similarity in the in vivo /in vitro  metabolic properties, a \\nstudy using several dose levels may not be necessary. In such cases, the Extended One -Generation \\nRepro ductive Toxicity Study could be conducted using a control group and a single dose of at least 1000 \\nmg/kg body weight/day. However, should evidence for reproductive or developmental toxicity be found \\nat this limit dose, further studies at lower dose levels will be required to identify a NOAEL. These limit \\ntest considerations apply only when human exposure does not indicate the need for a higher dose level.  \\nPROCEDURES  \\nExposure of offspring']\n",
      "['OECD/OCDE                      443 â”‚ 7 \\n \\nÂ© OECD 2018    \\n      offspring. In these cases, direct dosing of pups during the lactation period should be considered based on \\navailable TK information, offspring toxicity or changes in  bio-markers (3) (4). Careful consideration of \\nbenefits and disadvantages should be made prior to conducting direct -dosing studies on nursing pups (5).  \\nDosing schedule and administration of doses']\n",
      "['27. Some i nformation  on oestrous cycles, male and female reproductive tract histopathology and \\ntesticular/epididymal sperm analysis may be available from previous repeat -dose toxicity studies of \\nadequate duration. The duration of the pre -mating treatment in the Extended One -Generation \\nReproductive Toxicity Study is therefore  aimed at the detection of effects on functional changes that may \\ninterfere with mating behaviour and fertilisation. The pre -mating treatment  should be sufficiently long to \\nachieve steady -state exposure con ditions in P males and females.  A 2-week pre -mating treatment for \\nboth sexes is considered adequate in most cases. For females, this covers 3 -4 complete oestrous cycles \\nand should be sufficient to detect any adverse effects on cyclicity. For males, this is  equivalent to the \\ntime required for epididymal transit of maturing spermatozoa and should allow the detection of post -\\ntesticular effects on sperm (during the final stages of spermiation and epididymal sperm maturation) at \\nmating.  At the time of terminati on, when testicular and epididymal histopathology and analysis of sperm \\nparameters are scheduled, the P and F 1 males, will have been exposed for at least one entire \\nspermatogenic process  (6) (7) (8) (9) and GD 151  (40).']\n",
      "['28. Pre-mating exposure scenarios for males could be adapted if testicular toxicity (impairment of \\nspermatogenesis) or effects on sperm integrity and function have been clearly identified in previous \\nstudies. Similarly, for females, known effects of t he test chemical  on the oestrous cycle and thus sexual \\nreceptivity, may justify different pre -mating exposure scenarios. In special cases it may be acceptable \\nthat treatment of the P females is initiated only after a sperm -positive smear has been obtained (see GD \\n151 (40)).']\n",
      "['29. Once the pre -mating dosing period is established, the animals should be treated with the test \\nchemical  continuously on a 7 -days/week basis until necropsy. All animals should be dosed by the same  \\nmethod. Dosing should continue during the 2-week mating period  and, for P females, throughout \\ngestation and lactation  up to the day of termination after weaning. Males should be treated in the same \\nmanner until termination at the time when the F1 animals are weaned . For necropsy, priority should be \\ngiven to females which should be necropsied on the same/similar day of lactation. Necropsy of males can \\nbe spread over a larger number of days, depending on laboratory facilities. Unless already initiat ed \\nduring the lactation period,  direct dosing of the selected F1 males and females should begin at weaning \\nand continue until  scheduled necropsy, depending on cohort assignment .']\n",
      "['30. For substances administered via th e diet or drinking water, it is important to ensure that the \\nquantities of the test chemical  involved do not interfere with normal nutrition or water balance. When the \\ntest chemical  is administered in the diet, either a constant dietary concentration (ppm)  or a constant dose \\nlevel in terms of the body weight of the animal may be employed; the option chosen should be specified.']\n",
      "['8 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      dose during the last week of pregnancy may have to be adjusted to prevent administration of an \\nexcessively toxic dose to the dam. Females should not be treated by gavage, or any other route of \\ntreatment wher e the animal needs to be handled, on the day of parturition; omission of test chemical  \\nadministration on that day is preferable to a disturbance of the birth process.  \\nMating']\n",
      "['32. Each P female should be placed with a single, randomly selected, unrelated male from the same \\ndose group (1:1 pairing) until evidence of copulation is observed or 2 weeks have elapsed. If there are \\ninsufficient males, for example due to male death before p airing, then male(s) which have already mated \\nmay be paired (1:1) with a second female(s) such that all females are paired. Day 0 of pregnancy is \\ndefined as the day on which mating evidence is confirmed (a vaginal plug or sperm are found). Animals \\nshould b e separated as soon as possible after evidence of copulation is observed. If mating has not \\noccurred after 2 weeks, the animals should be separated without further opportunity for mating. Mating \\npairs should be clearly identified in the data.  \\nLitter size']\n",
      "['33. On day 4 after birth, the size of each litter may be adjusted by eliminating extra pups by \\nrandom selection to yield, as nearly as possible, five males and five females per litter. Selective \\nelimination of pups, e.g. based upon body weight, is not appropriate. Whenever the number of male or \\nfemale pups prevents having five of each sex per litter, partial adjustment (for example, six males and \\nfour females) is acceptable.  \\nSelection of pups for post -weaning studies (see Figure 1)']\n",
      "['OECD/OCDE                      443 â”‚ 9 \\n \\nÂ© OECD 2018    \\n      35. Should there be an insufficient number of pu ps in a litter to serve all cohorts, the cohort 1 takes \\nprecedence, as it can be extended to produce an F 2 generation. Additional pups may be assigned to any of \\nthe cohorts in case of specific concern, e.g. if a chemical is suspected to be a neurotoxicant,  \\nimmunotoxicant or reproductive toxicant. These pups may be used for examinations at different \\ntimepoints or for the evaluation of supplementary endpoints. Pups not assigned to cohorts will be \\nsubmitted to clinical biochemistry (paragraph  56) and gross nec ropsy ( paragraph  69). \\nSecond mating of the P animals']\n",
      "['36. A second mating is not normally recommended for the P animals, as it comes at the expense of \\nlosing important information on the number of implantation sites (and thus post -implantation and peri -\\nnatal loss data, indicators of a possible teratogenic potential) for the first litter. The need to verify or \\nelucidate an effect in exposed females would be served better by extending the study to include a mating \\nof th e F 1 generation. However, a second mating of the P males with untreated females is always an \\noption to clarify equivocal findings or for further characterisation of effects on fertility observed in the \\nfirst mating.  \\nIN-LIFE OBSERVATIONS  \\nClinical observations']\n",
      "['37. For the P and the selected F1 animals, a general clinical observation is made once a day. In the \\ncase of gavage dosing, the timing of clinical observations should be prior to and post dosing (for possi ble \\nsigns of toxicity associated with peak plasma concentration). Pertinent behavioural changes, signs of \\ndifficult or prolonged parturition and all signs of toxicity are recorded. Twice daily, during the weekend \\nonce daily, all animals are observed for se vere toxicity, morbidity and mortality.']\n",
      "['38. In addition, a more detailed examination of all P and F1 animals (after weaning) is conducted on \\na weekly basis and could conveniently be performed on an occasion when the a nimal is weighed, which \\nwould minimize handling stress. Observations should be carefully conducted and recorded using scoring \\nsystems that have been defined by the testing laboratory. Efforts should be made to ensure that variations \\nin the test conditions are minimal. Signs noted should include, but not be limited to, changes in skin, fur, \\neyes, mucous membranes, occurrence of secretions and excretions and autonomic activity ( e.g. \\nlacrimation, piloerection, pupil size, unusual respiratory pattern). Changes in gait, posture, response to \\nhandling, as well as the presence of clonic or tonic movements, stereotypy ( e.g. excessive grooming, \\nrepetitive circling) or bizarre behaviour ( e.g. self-mutilation, walking backwards) should also be \\nrecorded .  \\nBody weight and  food/water consumption']\n",
      "['39. P animals are weighed on the first day of dosing and at least weekly thereafter. In addition, P \\nfemales are weighed during lactation on the same days as the weighing of the pups in their l itters  (see \\nparagraph  45). All F 1 animals are weighed individually at weaning ( PND  21) and at least weekly \\nthereafter. Body weight is also recorded  on the day when they attain puberty (completion of  preputial \\nseparation or vaginal patency).  All animals are weighed at sacrifice.']\n",
      "['10 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      Oestrous cycles']\n",
      "['41. Preliminary information of test chemical -related effects on the oestrous cycle may already be \\navailable from previous repeat -dose toxicity studies, and may be used in designing a test chemical -\\nspecific protocol for the Extended One -Generation Reproductive Toxicity Study. Normally the \\nassessment of oestrous cyclicity (by vaginal cytology) will start at the beginning of the treatment period \\nand continue until confirmation of mating or the end of the 2 -week mating period. If females have been \\nscreened for normal oestrous cycles before treatment, the n it is useful to continue smearing as treatment \\nstarts, but if there is concern about non -specific effects at the start of treatment (such as an initial marked \\nreduction in food consumption) then animals may be allowed to adapt to treatment for up to two weeks \\nbefore the start of the 2 -week smearing period leading into pairing. If the female treatment period is \\nextended in this way ( i.e. to a 4 -week pre -mating treatment) then consideration should be made to \\npurchasing animals youngerand to extending the pe riod of male treatment before pairing. When \\nobtaining vaginal/cervical cells, care should be taken to avoid disturbance of mucosa and subsequently, \\nthe induction of pseudopregnancy (10) ( 11).']\n",
      "['42. Vaginal smears should  be examined daily for all F 1 females in cohort 1A, after the onset of \\nvaginal patency, until the first cornified smear is recorded, in order to determine the time interval \\nbetween these two events. Oestrous cycles for all  F1 females in  cohort 1A should al so be monitored for a \\nperiod of two weeks, commencing around PND  75. In addition, should mating of the F1 generation be \\nnecessary, the vaginal cytology in cohort 1B will  be followed   from the time of pairing  until mating \\nevidence is detected.  \\nMating and pr egnancy']\n",
      "['43. In addition to the standard endpoints ( e.g. body weight, food consumption, clinical observations \\nincluding mortality/morbidity checks), the dates of pairing, the date of insemination and the date of \\nparturition are recorded and the precoital interval (pairing to insemination) and the duration of pr egnancy \\n(insemination to parturition) are calculated. The P females should be examined carefully at the time of \\nexpected parturition for any signs of dystocia. Any abnormalities in nesting behaviour or nursing \\nperformance should be recorded.']\n",
      "['44. The day on which parturition occurs is lactation day 0 (LD 0) for the dam and postnatal day 0 \\n(PND  0) for the offspring . Alternatively, all comparisons may also be based on post -coital time to \\neliminate confounding of postnata l development data, by differences in the duration of pregnancy; \\nhowever, timing relative to parturition should also be recorded. This is especially important when the test \\nchemical  exerts an influence on the duration of pregnancy.  \\nOffspring parameters']\n",
      "['OECD/OCDE                      443 â”‚ 11 \\n \\nÂ© OECD 2018    \\n      excretions and autonomic activity. Changes in gait, posture, response to handling, as well as the presence \\nof clonic or tonic movements, stereotypy or bizarre behaviour, should also be recorded.']\n",
      "['46. The anogenital distance (AGD) of each pup should be measured on at least one occasion from \\nPND 0 through PND 4 . Pup body weight should be collected on the day the AGD is measured and the \\nAGD should be normalized to a measure of pup size, preferably the cube root of body weight (12). The \\npresence  of nipples/areolae in male pups should be checked on PND  12 or 13.']\n",
      "['47. All selected F1 animals are evaluated daily for balano -preputial separation or vaginal patency \\nfor male/female respectively commencing before the expected day for achievement of these endpoints to \\ndetect if sexual maturation occurs early. Any abnormalities of genital org ans, such as persistent vaginal \\nthread, hypospadia or cleft penis, should be noted. Sexual maturity of F 1 animals is compared to physical \\ndevelopment by determining age and body weight at balano -preputial separation or vaginal opening for \\nmale/female respe ctively (13). \\nAssessment of potential developmental neurotoxicity (cohort s 2A and 2B)']\n",
      "['48. Ten male and 10 female cohort 2A animals  and 10  male and 10 female cohort 2B animals , from \\neach treatment group ( for each cohor t: 1 male or 1 female per litter; all litters represented by at least 1 \\npup; randomly selected) should be used for neurotoxicity assessments. Cohort 2A animals should be \\nsubjected to auditory startle, functional observational battery, motor activity  (see paragraph s 49-51), and \\nneuropathology assessments  (see paragraph s 75-76). Efforts should be made to ensure that variations in \\nall test conditions are minimal and are not systematically related to treatment. Among the variables that \\ncan affect behaviour  are sound level (e.g. intermittent noise), temperature, humidity, lighting, odors, time \\nof day, and environmental distractions. Results of the neurotoxicity assays should be interpreted in \\nrelation to appropriate historical control reference ranges. Cohort 2B animals should be used for \\nneuropathology assessment on PND 21 or PND 22  (see paragraph s 75-76).']\n",
      "['49. An auditory startle test should be performed on PND 24 (Â±1 day) using animals in cohort 2A.  \\nThe day of testing shou ld be counterbalanced across treated and control groups. Each session consists of \\n50 trials.  In performing the auditory startle test, the mean response amplitude on each block of 10 trials \\n(5 blocks of 10 trials) should be determined, with test conditions  optimized to produce intra -session \\nhabituation.  These procedures should be consistent with OECD TG 426 (35).']\n",
      "['12 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      increases in activity). Each device should be tested by standard procedures to ensure, to the extent \\npossible, reliability of operation across devices  and across days. To the extent possible, treatment groups \\nshould be balanced across devices. Treatment groups should be counter -balanced across test times to \\navoid confounding by circadian rhythms of activity.']\n",
      "['51. If existing information indicates the need for other functional testing ( e.g. sensory, social, \\ncognitive), these should be integrated without compromising the integrity of the other evaluations \\nconducted in the study. If this testing is performed in the same  animals as used for standard auditory \\nstartle, functional observational battery  and motor activity testing, different tests should be scheduled to \\nminimise the risk of compromising the integrity of these tests. Supplemental procedures may be \\nparticularly useful when empirical observation, anticipated effects, or mechanistic/mode -of-action \\nindicate a specific type of neurotoxicity.  \\nAssessment of potential developmental immunotoxicity (cohort 3)']\n",
      "['52. At PND 56 (Â±3 days) , 10 male and 10 female cohort 3 animals from each treatment group (1 \\nmale or 1 female per litter; all litters represented by at least 1 pup; randomly selected) should be used in a \\nT-cell dependant antibody response assay, i.e. the primary IgM antibody res ponse to a T -cell dependent \\nantigen, such as Sheep Red Blood Cells (SRBC) or K eyhole Limpet Hemocyanin (KLH), consistent with \\ncurrent immunotoxicity testing procedures (14) ( 15). The response may be evaluated by counting specific \\nplaque -forming cells (PFC)  in the spleen or by determining the titer of SRBC - or KLH -specific IgM \\nantibody in the serum by ELISA, at the peak of the response. Responses typically peak four (PFC \\nresponse) or five (ELISA) days after intravenous immunization .   If the primary antibody  response is \\nassayed by counting plaque -forming cells, it is permissible to evaluate subgroups of animals on separate \\ndays, provided that: subgroup immunization and sacrifice are timed so that PFCs are counted at the peak \\nof the response; that subgroups co ntain an equal number of male and female offspring from all dose \\ngroups, including controls; and that subgroups are evaluated at approximately the same postnatal age.  \\nExposure to the test chemical  will continue until the day before collecting spleens for t he PFC response \\nor serum for the ELISA assay.  \\nFollow -up assessment of potential reproductive toxicity (cohort 1B)']\n",
      "['53. Cohort 1B animals can be maintained on treatment beyond PND  90 and bred to obtain a F 2 \\ngeneration  if necessary. Males and females of the same dose group should be cohabited (avoiding the \\npairing of siblings) for up to two weeks, beginning on or after PND  90, but not exceeding PND 120. \\nProcedures should be similar to those for the P animals. However, ba sed on a weight of evidence, it may \\nsuffice to terminate the litters on PND  4 rather than follow them to weaning or beyond.  \\nTERMINAL OBSERVATION S \\nClinical biochemistry / Haematology']\n",
      "['OECD/OCDE                      443 â”‚ 13 \\n \\nÂ© OECD 2018    \\n      provide useful information under certain circumstance s. In addition, blood from all animals may be taken \\nand stored for possible analysis at a later time to help clarify equivocal effects or to generate internal \\nexposure data. If a second mating of P animals is not intended, the blood samples are obtained ju st prior \\nto, or as part of, the procedure at scheduled sacrifice. In the case animals are retained, blood samples \\nshould be collected a few days before the animals are mated for the second time. Unless existing data \\nfrom repeated -dose studies indicate that  the parameter is not affected by the test chemical , urinalysis \\nshould be performed prior to termination and the following parameters evaluated: appearance, volume, \\nosmolality or specific gravity, pH, protein, glucose, blood and blood cells, cell debris. U rine may also be \\ncollected to monitor excretion of test chemical  and/or metabolite(s).']\n",
      "['55. Systemic effects should also be monitored in F 1 animals. Fasted blood samples from a defined \\nsite are taken from ten randomly selected cohort 1A males and females per dose group at termination, \\nstored under appropriate conditions and subjected to standard clinical biochemistry, including the \\nassessment of serum levels for thyroid hormones (T4 and TSH), haematology (total and diff erential \\nleukocyte plus erythrocyte counts) and urinalysis assessments.']\n",
      "['56. The surplus pups at PND 4 are subject to gross necropsy and consideration given to measuring \\nserum thyroid hormone (T4) concentrations. If necessary, neonatal (PND 4) blood can be pooled by \\nlitters for biochemical/thyroid hormone analyses. Blood is also collected for T4 and TSH analysis from \\nweanlings subject to gross necropsy on PND 22 ( F1 pups not selected for cohorts).  \\nSperm parameters']\n",
      "['57. Sperm parameters should be measured in all P generation males unless there is existing data to \\nshow that sperm parameters are unaffected in a 90 -day study. Examination of sperm parameters should \\nbe performed in all c ohort 1A males.']\n",
      "['58. At termination, testis and epididymis weights are recorded for all P and F 1 (cohort 1A) males. \\nAt least one testis and one epididymis are reserved for histopathological examination. The remaining \\nepididymis is used for enumeration of cauda epididymis sperm reserves (16) ( 17). In addition, sperm \\nfrom the cauda epididymis (or vas deferens) is collected using methods that minimise damage for \\nevaluation of sperm motility and morphology (18).']\n",
      "['59. Sperm motility can either be evaluated immediately after sacrifice or recorded for later \\nanalysis. The percentage of progressively motile sperm could be determined either subjectively or \\nobjectively by computer -assisted mot ion analysis  (19) (20) (21) (22) (23) (24). For the evaluation of \\nsperm morphology, an epididymal (or vas deferens) sperm sample should be examined as fixed or wet \\npreparations (25) and at least 200 spermatozoa per sample classified as either normal (both head and \\nmidpiece/tail appear normal) or abnormal. Examples of morphologic sperm abnormalities would include \\nfusion, isolated heads, and misshapen heads and/or tails (26). Misshapen or large sperm heads may \\nindicate defects in spermiation.']\n",
      "['60. If sperm samples are frozen, smears fixed and images for sperm motility analysis recorded at \\nthe time of necropsy (27), subsequent analysis may be restricted to control and high -dose males.  \\nHowever, if treatment -related e ffects are observed, the lower dose groups should also be evaluated.  \\nGross necropsy']\n",
      "['14 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      condition and dead pups should be recorded and, when not macerated, examined for possible defect s \\nand/or cause of death and preserved.']\n",
      "['62. For adult P and F1 females, a vaginal smear is examined on the day of necropsy to determine \\nthe stage of the oestrous cycle  and allow correlation with histopathology in repro ductive organs. The \\nuteri of all P females (and F 1 females, if applicable) are examined for the presence and number of \\nimplantation sites, in a manner which does not compromise histopathological evaluation.  \\nOrgan weight and tissue preservation â€“ P and F 1 adult animals']\n",
      "['63. At the time of termination, body weights and wet weights of the organs listed below from all P \\nanimals  and all F 1 adults, from relevant cohorts (as outlined below), are determined as soon as possible  \\nafter dissection to avoid drying. These organs should then be preserved under appropriate conditions . \\nUnless specified otherwise, paired organs can be weighed individually or combined, consistent with the \\ntypical practice of the performing laboratory.  \\n\\uf0b7 Uterus (with oviducts and cervix) , ovaries  \\n\\uf0b7 Testes, epididymides (total and cauda  for the samples used for sperm counts ) \\n\\uf0b7 Prostate (dorsolateral and ventral part s combined).  Care should be exercised when trimming the \\nprostate complex to avoid puncture of the fl uid filled seminal vesicles.  In the event of a \\ntreatment -related effect on total prostate weight, the dorsolateral and ventral segments should be \\ncarefully dissected after fixation, and weighed separately.  \\n\\uf0b7 Seminal vesicles with coagulating glands and thei r fluids (as one unit)  \\n\\uf0b7 Brain, liver, kidneys, heart, spleen, thymus, pituitary, thyroid (post -fixation), adrenal glands and \\nknown target organs or tissues.']\n",
      "['64. In addition to the organs listed above, samples of peripheral nerve, muscle, spinal cord, eye \\nplus optic nerve, gastrointestinal tract, urinary bladder, lung, trachea (with thyroid and parathyroid \\nattached), bone marrow, vas deferens (males), mammary gland  (males and females) and vagina should be \\npreserved under appropriate conditions.']\n",
      "['65. Cohort 1A animals have all organs weighed and preserved for histopathology.']\n",
      "['OECD/OCDE                      443 â”‚ 15 \\n \\nÂ© OECD 2018    \\n      67. Cohort 1B animals should have the following organs weighed and corresponding tissues \\nprocessed to the block stage:  \\n- Vagina (not weighed)  \\n- Uterus with cervix  \\n- Ovaries  \\n- Testes (at least one)  \\n- Epididymides  \\n- Seminal vesicles and coagulating glands  \\n- Prostate  \\n- Pituitary  \\n- Identified target organs  \\n \\nHistopathology in cohort 1B would be conducted if results from cohort 1A are equivocal or in cases of \\nsuspected reproductive  or endocrine toxicants.']\n",
      "['68. Cohorts 2A and 2B: Developmental neurotoxicity testing (PND 21 or PND 22 and adult \\noffspring). Cohort 2A animals are terminated after behavioural testing, with brain weight recorded and \\nfull neurohistopathology for purposes of neurotoxicity assessment. Cohort 2B animals are terminated on \\nPND 21 or PND 22, with brain weight recorded and microscopic examination of the brain for purposes \\nof neurotoxicity assessment. Perfusion fixation is req uired for cohort 2A animals and optional for cohort \\n2B animals, as provided in OECD TG 426 (35). \\nOrgan weight and tissue preservation â€“ F1 weanlings']\n",
      "['69. The pups not selected for cohorts, including runts, are terminated after weaning, on PND 22 , \\nunless the results indicate the need for further in -life investigations. Terminated pups are subjected to \\ngross necropsy including an assessment of the reproductive organs , as described in paragraph s 63 and 6 4. \\nFor up to 10 pups per sex per group, from as many litters as possible, brain, spleen, and thymus should \\nbe weighed and retained under appropriate conditions. In addition, mammary tissues for these male and \\nfemale pup s may be preserved for further microscopic analysis1 (see GD 151 (40)). Gross  abnormalities \\nand target tissues should be saved for possible histological examination.    \\nHistopathology â€“ P animals']\n",
      "['16 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      Histopathology â€“ F1 animals  \\nCohort 1 animals']\n",
      "['71. Full histopathology of the organs listed in paragraph s 63 and 6 4 is performed for all high -dose \\nand control adult cohort 1A animals. All litters should be represented by at least 1 pup per sex.  Organs \\nand tissues demonstrating treatment -related changes and all gross lesions should also be examined in all \\nanimals in the lower dose groups  to aid in de termining a NOAEL . For the evaluation of pre - and \\npostnatally induced effects on lymphoid organs also the histopathology on the collected lymph nodes and \\nbone marrow should be evaluated of 10 male and 10 female cohort 1A animals next to histopathological \\nevaluation of the thymus, spleen, and the adrenal glands already performed in all 1A animals.']\n",
      "['72.  Reproductive and endocrine tissues from a ll cohort 1B animals , processed to the block stage  as \\ndescribed in paragraph  67, should be examined for histopathology in cases of suspected reproductive or \\nendocrine toxicants. Cohort 1B should also undergo histological examination if results from cohort 1A \\nare equivocal.']\n",
      "['73. Ovaries of adult females should contain primordial and growing follicles, as well as corpora \\nlutea; therefore, a histopathological examination should be aimed at detecting a quantitative evaluation of \\nprimordial and small growing follicles, as wel l as corpora lutea, in F 1 females; the number of animals, \\novarian section selection, and section sample size should be statistically appropriate for the evaluation \\nprocedure used. Follicular enumeration may first be conducted on control and high -dose anima ls, and in \\nthe event of an adverse effect in the latter, lower doses should be examined. Examination should include \\nenumeration of the number of primordial follicles, which can be combined with small growing follicles, \\nfor comparison of treated and control  ovaries  (see GD 151 (40)) . Corpora lutea assessment should be \\nconducted in parallel with oestrous cyclicity testing so that the stage of the cycle can be taken into \\naccount in the assessment. Oviduct, uterus and vagina are examined for appropriate organ -typic \\ndevelopment.']\n",
      "['74. Detailed testicular histopathology examinations are conducted on the F 1 males in order to \\nidentify treatment -related effects on testis differentiation and development and on spermatogenesis  (38).  \\nWhen possible, sections of the rete testis should be examined. Caput, corpus, and cauda of the \\nepididymis and the vas deferens are examined for appropriate organ -typic development, as well as for the \\nparameters required for the P males.  \\nCohort 2 animals']\n",
      "['75. Neurohistopathology is performed for all high -dose and control cohort 2A animals per sex \\nfollowing completion of neurobehavioral testing ( after PND 75, but not to exceed PND 90). Brain \\nhistopathology is performed for all high -dose and control cohort 2B animals per sex on PND 21 or PND']\n",
      "['22. Organs or tissues demonstrating treatment -related changes should also be examined for the animals \\nin the lower dose groups  to aid in determining a NOAEL . For cohort 2A and 2B animals, multiple \\nsections are examined from the brain to allow examination of olfactory bulbs, cerebral cortex, \\nhippocampus, basal ganglia, thalamus, hypothalamus, mid -brain (thecum, tegmentum, and cere bral \\npeduncles), brain -stem and cerebellum. For cohort 2A only, the eyes (retina and optic nerve) and samples \\nof peripheral nerve, muscle and spinal cord are examined. All neurohistological procedures should be \\nconsistent with OECD TG 426 (35).']\n",
      "['OECD/OCDE                      443 â”‚ 17 \\n \\nÂ© OECD 2018    \\n      taken at each landmark (level) in order to select the most homologous and representative section for the \\nspecific brain area to be evaluated. The neuropathologist should exercise a ppropriate judgment as to \\nwhether sections prepared for measurement are homologous with others in the sample set and therefore \\nsuitable for inclusion, since linear measurements in particular may change over a relatively short distance \\n(28).  Non -homologous  sections should not be used. While the objective is to sample all animals reserved \\nfor this purpose (10/sex/dose level), smaller numbers may still be adequate.  However, samples from \\nfewer than 6 animals/sex/dose level would generally not be considered su fficient for the purposes of this \\nTest Guideline .  Stereology may be used to identify treatment -related effects on parameters such as \\nvolume or cell number for specific neuroanatomic regions. All aspects of the preparation of tissue \\nsamples, from tissue fi xation, through the dissection of tissue samples, tissue processing, and staining of \\nslides, should employ a counterbalanced design, such that each batch contains representative samples \\nfrom each dose group. When morphometric or stereological analyses are to be used, then brain tissue \\nshould be embedded in appropriate media at all dose levels at the same time in order to avoid shrinkage \\nartifacts associated with prolonged storage in fixative.  \\nREPORTING  \\nData']\n",
      "['77. Data a re reported individually and summarised in tabular form. Where appropriate, for each test \\ngroup and each generation, the following should be reported: number of animals at the start of the test, \\nnumber of animals found dead during the test or killed for hu mane reasons, time of any death or humane \\nkill, number of fertile animals, number of pregnant females, number of females giving birth to a litter, \\nand number of animals showing signs of toxicity. A description of the toxicity, including time of onset, \\nduration, and severity should also be reported.']\n",
      "['78. Numerical results should be evaluated by an appropriate, and accepted statistical method.  The \\nstatistical methods should be selected as part of the study design and  should appropriately address non -\\nnormal data ( e.g. count data), censored data ( e.g. limited observation time), non -independence ( e.g. litter \\neffects and repeated measures), and unequal variances. Generalized linear mixed models and dose -\\nresponse models cover a broad class of analytical tools that may be appropriate for the data generated \\nunder this TG. The report should include sufficient information on the method of analysis and the \\ncomputer program employed, so that an independent reviewer/statistician can e valuate/re -evaluate the \\nanalysis.  \\nEvaluation of results']\n",
      "['79. The findings should be evaluated in terms of the observed effects, including necropsy and \\nmicroscopic findings. The evaluation includes the relationship, or lack thereof, between the dose and the \\npresence, incidence, and severity of abnormalities, includin g gross lesions.  Target organs, fertility, \\nclinical abnormalities, reproductive and litter performance, body weight changes, mortality and any other \\ntoxic and developmental effects should also be assessed. Special attention should be given to sex -specific  \\nchanges. The physico -chemical properties of the test chemical , and when available, TK data, including \\nplacental transfer and milk excretion, should be taken into consideration when evaluating the test results.  \\nTest report']\n",
      "['20 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n       \\nCohort 3 paramete rs \\n\\uf0b7 Serum IgM antibody titres (sensitization to SRBC or KLH), or splenic IgM PFC units \\n(sensitization to SRBC) ; \\n\\uf0b7 Performance of the TDAR method should be confirmed as part of the optimisation process by \\nlaboratory setting up the assay for the first time, and  periodically ( e.g. yearly) by all laboratories ; \\n  \\n\\uf0b7 Discussion of the overall interpretation of the data based on the results, including a conclusion of \\nwhether or not the chemical caused developmental immunotoxicity and the NOAEL ;  \\n \\nDiscussion of results  \\n \\nConclusions, including NOAEL values for parental and offspring effects  \\n \\nAll information not obtained during the study, but useful for the interpretation of the results ( e.g. \\nsimilarities of effects to any known neurotoxicants) , should also be provided.  \\nInterpretation Of  Results']\n",
      "['81. An Extended One -Generation Reproductive Toxicity Study will provide information on the \\neffects of repeated exposure to a substance during all phases of the reproductive cycle, as necessary. In \\nparticular, the study provides information on the reproductive system, and on development, growth, \\nsurvival, and functional endpoints of offspring up to PND  90.']\n",
      "['82. Interpretation of the results of the s tudy should take into account all available information on \\nthe substance, including physico -chemical, TK and toxicodynamic properties, available relevant \\ninformation on structural analogues, and results of previously -conducted toxicity studies with the test \\nchemical  (e.g. acute toxicity, toxicity after repeated application, mechanistic studies and studies assessing \\nif there are substantial qualitative and quantitative species differences in in vivo /in vitro  metabolic \\nproperties). Gross necropsy and organ we ight results should be assessed in context with observations \\nmade in other repeat -dose studies, when feasible. Decreases in offspring growth might be considered in \\nrelationship to an influence of the test chemical  on milk composition (29).  \\nCohort 2 (Devel opmental neurotoxicity)']\n",
      "['83. Neurobehavioral and neuropathology results should be interpreted in the context of all findings, \\nusing a weight -of-evidence approach with expert judgment.  Patterns of behavioural or morphol ogical \\nfindings, if present, as well as evidence of dose -response should be discussed. The evaluation of \\ndevelopmental neurotoxicity, including human epidemiological studies or case reports, and experimental \\nanimal studies ( e.g. toxicokinetic data, structu re-activity information, data from other toxicity studies) \\nshould be included in this characterization. Evaluation of data should include a discussion of both the \\nbiological and statistical significance. The evaluation should include the relationship, if a ny, between \\nobserved neuropathological and behavioural alterations. For guidance on the interpretation of \\ndevelopmental neurotoxicity results, refer to OECD TG 426 (35) and Tyl et al., 2008 (31). \\nCohort 3 (Developmental immunotoxicity)']\n",
      "['OECD/OCDE                      443 â”‚ 21 \\n \\nÂ© OECD 2018    \\n      Effects established by TDAR may be less meaningful in case of other toxicities observed at lower \\nexposure  concentrations .']\n",
      "['22 â”‚ 443                        OECD/OCDE \\nÂ© OECD 2018    \\n      LITERATURE  \\n \\n(1) Cooper, R.L., J.C . Lamb,  S.M.  Barlow, K. Bentley, A.M.  Brady, N. Doerr, D.L. Eisenbrandt, P.A. \\nFenner -Crisp, R.N. Hines, L.F.H. Irvine, C.A.  Kimmel, H. Koeter, A.A.  Li, S.L. Makris, L.P.  \\nSheets, G.J.A. Speijers and  K.E. Whitby (2006) , â€œA Tiered A pproach to Life S tages Testing for \\nAgricultural Chemical S afety  Assessment â€, Critical Reviews in Toxicology , 36, 69 -98. \\n(2) Thigpen, J.E., K.D.R. Setchell, K.B. Ahlmark, J. Locklear, T. Spahr, G.F. Leviness, M.F. Goelz, J.K. \\nHaseman, R.R. Newbold, and D.B. Forsythe (1999) , â€œPhytoestrogen C ontent of Purified Open and \\nClosed F ormula Laboratory Animal D ietsâ€, Lab. Anim. Sci. , 49, 530 - 536. \\n(3) Zoetis, T.  and I. Walls (2003) , Principles and Practices for Direct Dosing of Pre -Weaning Mammals \\nin Toxicity Testing and Research , ILSI Press, Washington, DC.  \\n(4) Moser , V.C., I.  Walls  and T. Zoetis (2005) , â€œDirect Dosing of Preweaning R odents in Toxicity \\nTesting and Research: Deliberations of an ILSI RSI Expert Working G roupâ€, International \\nJournal of Toxicology , 24, 87 -94. \\n(5) Conolly , R.B.,  B.D. Beck , and J.I. Goodman  (1999) , â€œStimulating Research to Improve the Scientific \\nBasis of Risk A ssessment â€, Toxicological Sciences , 49, 1 -4. \\n(6) Ulbrich, B. and  A.K. Palmer (1995),  â€œDetection of Effects on Male Reproduction â€“ a Literature \\nSurvey â€, Journal of the American College of Toxicol ogists , 14, 293 -327.', 'Survey â€, Journal of the American College of Toxicol ogists , 14, 293 -327. \\n(7) Mangelsdorf, I., J. Buschmann and B. Orthen (2003) , â€œSome Aspects R elating to the Evaluation of \\nthe Effects of Chemicals on Male F ertility â€, Regulatory Toxicology and Pharmacology , 37, 356 -']\n",
      "[Document(page_content='OECD/OCDE  416\\nAdopted:\\n22nd January 2001\\n1/13OECD GUIDELINE FOR TESTING OF CHEMICALS\\nTwo-Generation Reproduction Toxicity Study\\nINTRODUCTION', metadata={'source': 'data/OECD TG 416.pdf', 'page': 0}), Document(page_content='1.', metadata={'source': 'data/OECD TG 416.pdf', 'page': 0}), Document(page_content='In Copenhagen in June 1995, an OECD Working Group on Reproduction and Developmental', metadata={'source': 'data/OECD TG 416.pdf', 'page': 0}), Document(page_content='1. In Copenhagen in June 1995, an OECD Working Group on Reproduction and Developmental\\nToxicity discussed the need to update existing OECD  Test Guidelines for reproduction and developmental\\ntoxicity and the development of new Guidelines for endpoints not yet covered.  The Working Group\\nrecommended that the Guideline for the Two-generation Reproduction Toxicity Study should be revised,based on proposals received from US and Germany.  The Working Group reached agreement on all major\\nelements of the revised version of this Guideline (1).\\nINITIAL CONSIDERATIONS', metadata={'source': 'data/OECD TG 416.pdf', 'page': 0}), Document(page_content='2.', metadata={'source': 'data/OECD TG 416.pdf', 'page': 0})]\n"
     ]
    }
   ],
   "source": [
    "documents = load_documents()\n",
    "chunks = split_documents(documents)\n",
    "\n",
    "print(chunks[:5])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "sciencegpt",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
